US Patent

US11827646 — Compounds for treating spinal muscular atrophy

Method of Use · Assigned to Hoffmann La Roche Inc · Expires 2036-01-25 · 10y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds of formula (I) and their use as medicaments, as well as their manufacture and pharmaceutical compositions.

USPTO Abstract

The present invention provides compounds of formula (I)wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.

Drugs covered by this patent

Evrysdi (RISDIPLAM) · Roche

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1943`	—	Evrysdi
`U-1943`	—	Evrysdi

Patent Metadata

Patent number: US11827646
Jurisdiction: US
Classification: Method of Use
Expires: 2036-01-25
Drug substance claim: No
Drug product claim: No
Assignee: Hoffmann La Roche Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.